46 PART ONE | CISPLATIN-INDUCED ACUTE KIDNEY INJURY 17. Zeng X, McMahon GM, Brunelli SM et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 2014; 9:12-20. 18. Crona DJ, Faso A, Nishijima TF et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. The Oncologist 2017;22:609-19. 19. Yokoo K, Murakami R, Matsuzaki T et al. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 2009;13:578-84. 20. Horie S, Oya M, Nangaku M et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 2018;22:210-44. 21. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-45. 22. Faig J, Haughton M, Taylor RC et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol 2018; 41:432-40. 23. Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev 2015;16:1117-22. 24. Motwani SS, McMahon GM, Humphreys BD et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 2018;36:682-8. 25. de Jongh FE, van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003;88:1199-06. 26. Bhat ZY, Cadnapaphornchai P, Ginsburg K et al. Understanding the risk Factors and long-term consequences of cisplatinassociated acute kidney injury: an observational cohort study. PLoS One 2015;10:e0142225. 27. Stewart DJ, Dulberg CS, Mikhael NZ et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-08. 28. Mizukami N, Yamauchi M, Koike K et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebocontrolled study. J Pain Symptom Manage 2014;47:542-50. 29. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016;375:134-42. 30. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012;82:51624. 31. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014;371:58–66. 32. Strojan P, Vermorken JB, Beitler JJ et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 2016;38 Suppl 1 2151-8.
RkJQdWJsaXNoZXIy MjY0ODMw